NMTC1
MCID: THY109
MIFTS: 58

Thyroid Cancer, Nonmedullary, 1 (NMTC1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 1

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 1:

Name: Thyroid Cancer, Nonmedullary, 1 57
Papillary Thyroid Carcinoma 12 53 29 6 15 73
Familial Nonmedullary Thyroid Cancer, Papillary 57 53 75
Nonmedullary Thyroid Carcinoma, Papillary 57 53 75
Non-Medullary Thyroid Carcinoma 75 73
Papillary Carcinoma of Thyroid 57 75
Thyroid Carcinoma, Papillary 76 13
Nmtc1 57 75
Pact 57 75
Papillary Carcinoma of Thyroid; Pact; Ptc; Tpc 57
Familial Nonmedullary Thyroid Gland Carcinoma 73
Papillary Carcinoma of the Thyroid Gland 12
Familial Non-Medullary Thyroid Cancer 75
Cancer, Thyroid, Nonmedullary, Type 1 40
Thyroid Carcinoma, Nonmedullary, 1 13
Thyroid Carcinoma, Nonmedullary 1 73
Thyroid Cancer, Non-Medullary, 1 75
Nonmedullary Thyroid Carcinoma 1 6
Nonmedullary Thyroid Carcinoma 75
Cancer, Thyroid, Nonmedullary 40
Thyroid Papillary Carcinoma 55
Thyroid Cancer, Papillary 44
Papillary Thyroid Cancer 55
Fnmtc 75
Nmtc 75
Ptc 75
Tpc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
thyroid cancer, nonmedullary, 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 188550
Disease Ontology 12 DOID:3969
NCIt 50 C4035
SNOMED-CT 68 4797003
MedGen 42 C0238463
SNOMED-CT via HPO 69 263681008 3716002 255029007

Summaries for Thyroid Cancer, Nonmedullary, 1

OMIM : 57 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular (188470), Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100; Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). PTC is characterized by distinctive nuclear alterations including pseudoinclusions, grooves, and chromatin clearing. PTCs smaller than 1 cm are referred to as papillary microcarcinomas. These tumors have been identified in up to 35% of individuals at autopsy, suggesting that they may be extremely common although rarely clinically relevant. PTC can also be multifocal but is typically slow-growing with a tendency to spread to lymph nodes and usually has an excellent prognosis (summary by Bonora et al., 2010). (188550)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 1, also known as papillary thyroid carcinoma, is related to struma ovarii and differentiated thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 1 is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are miRs in Muscle Cell Differentiation and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Emend and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are goiter and papillary thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer.

NIH Rare Diseases : 53 Papillary thyroid carcinoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of certain cells (follicular cells) of the thyroid. Many people with papillary thyroid carcinoma have no signs or symptoms of the condition. When present, symptoms may include a small lump at the base of the neck, hoarseness, difficulty swallowing, trouble breathing, and pain in the neck or throat. Although people of all ages may be diagnosed with the condition, women between ages 30 and 50 are most commonly affected. The cause of papillary thyroid carcinoma is currently unknown. Risks for developing thyroid cancer include a history of high-dose external radiation treatments to the neck and radiation exposure during nuclear plant disasters. The best treatment options depend on many factors, but may include surgery, radiation therapy (including radioactive iodine therapy), chemotherapy and thyroid hormone therapy.

UniProtKB/Swiss-Prot : 75 Thyroid cancer, non-medullary, 1: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 76 Papillary thyroid cancer or papillary thyroid carcinoma is the most common type of thyroid cancer,... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 1

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 struma ovarii 31.3 NKX2-1 BRAF
2 differentiated thyroid carcinoma 30.8 NKX2-1 GAS8-AS1 BRAF
3 dermatomyositis 30.5 MIR222 MIR221
4 pituitary adenoma 30.5 HOTAIR H19
5 papillary thyroid microcarcinoma 30.5 NKX2-1 BRAF
6 diffuse large b-cell lymphoma 30.4 MIR221 HULC HOTAIR
7 lung cancer susceptibility 3 30.4 NKX2-1 LINC-ROR HOTAIR H19 BRAF
8 melanoma 30.3 BANCR BRAF H19 HOTAIR LINC-ROR MIR221
9 thyroid cancer 30.2 PVT1 PTCSC3 NKX2-1 HOTAIR H19 BRAF
10 renal cell carcinoma, nonpapillary 30.2 PVT1 NKX2-1 LINC-ROR HOTAIR H19
11 glioblastoma 30.2 PTCSC2 MIR222 MIR221 HOTAIR H19 BRAF
12 adamantinoma of long bones 30.1 PVT1 LINC-ROR HULC HOTTIP HOTAIR H19
13 esophageal cancer 30.1 PVT1 LINC-ROR HULC HOTTIP HOTAIR H19
14 ovarian cancer 30.1 BRAF H19 PVT1 MIR222 MIR221 MIR146A
15 bladder cancer 30.1 BANCR H19 HAGLR HOTAIR HULC MIR221
16 glioma 30.0 PVT1 PTCSC3 MIR222 MIR221 HULC HOTTIP
17 colorectal cancer 30.0 PVT1 MIR221 LINC-ROR HULC HOTTIP HOTAIR
18 hepatocellular carcinoma 29.9 PVT1 MIR222 MIR221 MIR146A LINC-ROR HULC
19 gastric cancer 29.9 PVT1 MIR222 MIR221 LINC-ROR HULC HOTTIP
20 multicentric papillary thyroid carcinoma 12.4
21 thyroid cancer, nonmedullary, 3 11.5
22 thiourea tasting 11.5
23 thyroid carcinoma, papillary, with papillary renal neoplasia 11.4
24 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 11.2
25 familial papillary or follicular thyroid carcinoma 11.1
26 thyroid cancer, nonmedullary, 2 11.1
27 thyroid cancer, nonmedullary, 4 11.1
28 thyroid cancer, nonmedullary, 5 11.1
29 papillary carcinoma 10.7
30 hashimoto thyroiditis 10.4
31 familial adenomatous polyposis 10.4
32 esophagus squamous cell carcinoma 10.4 HOTAIR BANCR
33 triple-receptor negative breast cancer 10.4 LINC-ROR HOTAIR
34 hyperparathyroidism 10.4
35 malignant glioma 10.3 PVT1 HOTTIP HOTAIR
36 primary hyperparathyroidism 10.3
37 gastric cardia adenocarcinoma 10.3 HOTAIR H19
38 oral squamous cell carcinoma 10.3 MIR221 MIR146A HOTAIR H19
39 coronary heart disease 1 10.3 MIR222 MIR221 HOTTIP H19
40 ovarian epithelial cancer 10.3 HULC HOTAIR HAGLR H19
41 gastrointestinal system cancer 10.3 HOTAIR H19 BANCR
42 kidney cancer 10.3 PVT1 HOTAIR H19
43 myeloma, multiple 10.3 PVT1 HOTAIR H19 BRAF
44 squamous cell carcinoma, head and neck 10.3 MIR221 HOTAIR H19 BRAF
45 langerhans cell histiocytosis 10.3
46 nodular goiter 10.3
47 histiocytosis 10.3
48 follicular adenoma 10.3
49 multiple endocrine neoplasia 10.3
50 pancreatic ductal adenocarcinoma 10.3 PVT1 MIR221 MIR146A HOTTIP HOTAIR H19

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 1:



Diseases related to Thyroid Cancer, Nonmedullary, 1

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 1

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
nonmedullary thyroid carcinoma (papillary)
goiter, multinodular


Clinical features from OMIM:

188550

Human phenotypes related to Thyroid Cancer, Nonmedullary, 1:

32
# Description HPO Frequency HPO Source Accession
1 goiter 32 HP:0000853
2 papillary thyroid carcinoma 32 HP:0002895
3 non-medullary thyroid carcinoma 32 HP:0040198

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 1

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
2
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
3
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
4
Sancuso 18 GRANISETRON ProStrakan September 2008
5
Clarinex 18 DESLORATADINE Schering-Plough February 2002
6
Patanase 18 OLOPATADINE HYDROCHLORIDE Alcon April 2008

Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
2 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
3 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
4 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
5 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1
6 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
7 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1
8 Hormone Antagonists Phase 3,Phase 2
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
10
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
11
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
12
Everolimus Approved Phase 2 159351-69-6 6442177
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
15
Indinavir Approved Phase 2 150378-17-9 5362440
16
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
17
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
18
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
19
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
20
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
21
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
22
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
23
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
24
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
25
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
26
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
27
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
28
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
29
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Tamoxifen Approved Phase 2 10540-29-1 2733526
32
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
33
Dabrafenib Approved, Investigational Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
34
Lenvatinib Approved, Investigational Phase 2 417716-92-8
35
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
36
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Trametinib Approved Phase 2 871700-17-3 11707110
39
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
40
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
43
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
44
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
46
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
47
Doxil Approved June 1999 Phase 2 31703
48
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
49
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
50 Hypoglycemic Agents Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
2 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
3 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
4 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
5 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
6 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
7 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
8 High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
9 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
10 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
11 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Completed NCT00559949 Phase 2 Selumetinib
14 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
15 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed NCT01286753 Phase 2 Vemurafenib
16 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
17 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
18 Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Completed NCT00630214 Phase 2
19 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
20 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
21 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
22 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
23 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
24 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
25 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
26 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
27 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
28 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
29 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
30 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
31 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
32 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
33 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
34 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
35 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer Recruiting NCT02138214 Phase 2
36 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
37 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
38 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib
39 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
40 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
41 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
42 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
43 Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer Active, not recruiting NCT02408887 Phase 2
44 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
45 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
46 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
47 Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting NCT01709292 Phase 2 Vemurafenib (All Groups);Vemurafenib (Post Surgery) - Group A + C
48 Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Not yet recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
49 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
50 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated NCT02012231 Phase 1, Phase 2 PLX8394

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 1

Cochrane evidence based reviews: thyroid cancer, papillary

Genetic Tests for Thyroid Cancer, Nonmedullary, 1

Genetic tests related to Thyroid Cancer, Nonmedullary, 1:

# Genetic test Affiliating Genes
1 Papillary Thyroid Carcinoma 29 CCDC6 NCOA4

Anatomical Context for Thyroid Cancer, Nonmedullary, 1

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 1:

41
Thyroid, Lymph Node, Bone, Lung, Pituitary, Endothelial, Myeloid

Publications for Thyroid Cancer, Nonmedullary, 1

Articles related to Thyroid Cancer, Nonmedullary, 1:

(show top 50) (show all 2279)
# Title Authors Year
1
Activity of ecto-5'-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes. ( 30184475 )
2019
2
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases. ( 30261209 )
2019
3
Fine mapping of 14q13 reveals novel variants associated with different histological subtypes of papillary thyroid carcinoma. ( 30350351 )
2019
4
Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis. ( 30146756 )
2019
5
High Expression of Yes-activated Protein-1 in Papillary Thyroid Carcinoma Correlates With Poor Prognosis. ( 28682834 )
2019
6
iTRAQ analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma. ( 29355489 )
2018
7
Malignant pleural effusion from papillary thyroid carcinoma diagnosed by pleural effusion cytology: A case report. ( 28960907 )
2018
8
Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma. ( 29287713 )
2018
9
Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma. ( 29280051 )
2018
10
A rare case of ectopic papillary thyroid carcinoma transformed into squamous cell carcinoma. ( 29451347 )
2018
11
miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1. ( 29427661 )
2018
12
Follow-up of parenchymal changes in the thyroid gland with diffuse autoimmune thyroiditis in children prior to the development of papillary thyroid carcinoma. ( 29872995 )
2018
13
Differentiation of the Follicular Variant of Papillary Thyroid Carcinoma From Classic Papillary Thyroid Carcinoma: An Ultrasound Analysis and Complement to Fine-Needle Aspiration Cytology. ( 28880405 )
2018
14
Risk factors stratifying malignancy of nodules in contralateral thyroid lobe in patients with pre-operative ultrasound indicated unilateral papillary thyroid carcinoma: A retrospective analysis from single centre. ( 29083503 )
2018
15
The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma. ( 29300379 )
2018
16
USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma. ( 29533940 )
2018
17
Preoperatively undiagnosed papillary thyroid carcinoma in patients thyroidectomized for benign multinodular goiter. ( 29641730 )
2018
18
Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro-A Clinically NodeA Negative Papillary Thyroid Carcinoma. ( 29238850 )
2018
19
Papillary thyroid carcinoma presenting as acute suppurative thyroiditis: A case report and review of the literature. ( 29447798 )
2018
20
Primary squamous cell carcinoma of the thyroid associated with papillary thyroid carcinoma and Hashimoto's thyroiditis. ( 29914738 )
2018
21
Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients. ( 29788738 )
2018
22
Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Arising in a Follicular Adenoma: a Diagnostic Dilemma. ( 30288010 )
2018
23
A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroid Carcinoma Presenting with Visual Disturbance without Hyperthyroidism. ( 30096503 )
2018
24
Poikiloderma-like cutaneous amyloidosis associated with papillary thyroid carcinoma. ( 28225149 )
2018
25
An Unusual Case Report: Occurrence of Renal Cell Carcinoma, Basal Cell Carcinoma and Chronic Lymphocytic Leukemia in a Case of Papillary Thyroid Carcinoma Treated with Radioactive Iodine. ( 30510343 )
2018
26
Live birth following laparoscopic fertility-sparing surgery for papillary thyroid carcinoma arising from mature ovarian cystic teratoma: A case report. ( 30546889 )
2018
27
Mutational Profile of Papillary Thyroid Carcinoma in an Endemic Goiter Region of North India. ( 30148098 )
2018
28
Ectopic Papillary Thyroid Carcinoma Mimicking Esophageal Cancer in FDG PET: A Case Report. ( 30394932 )
2018
29
Immunohistochemical and Molecular Analyses Focusing on Mesenchymal Cells in Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis. ( 30223266 )
2018
30
Can Ultrasound Alone Predict Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis? A Retrospective Analysis of 13 Cases, Focusing on the Stromal Area. ( 30250939 )
2018
31
Rapid Growth and Early Metastasis of Papillary Thyroid Carcinoma in an Adolescent Girl with Graves' Disease. ( 30092570 )
2018
32
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis. ( 30121940 )
2018
33
A First Report of Secondary Hemophagocytic Lymphohistiocytosis Associated With Papillary Thyroid Carcinoma. ( 29087969 )
2018
34
Hyperthyroidism and Papillary Thyroid Carcinoma in Thyrotropin Receptor D633H Mutant Mice. ( 30132406 )
2018
35
Partial thyrocyte-specific Gαs deficiency leads to rapid-onset hypothyroidism, hyperplasia, and papillary thyroid carcinoma-like lesions in mice. ( 29799790 )
2018
36
Breast tumour resembling tall cell variant of papillary thyroid carcinoma: case presentation (in a patient with Lynch syndrome). ( 29982234 )
2018
37
Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma: Molecular Characterization by Next-Generation Sequencing and Histopathological Comparison With Tall Cell Papillary Carcinoma of Thyroid. ( 30227763 )
2018
38
Simultaneous Pheochromocytoma, Paraganglioma, and Papillary Thyroid Carcinoma without Known Mutation. ( 30405919 )
2018
39
Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma. ( 30535496 )
2018
40
Papillary Thyroid Carcinoma Incidentally Found in Cervical Lymph Nodes During Neck Dissection for Patients With Tongue Squamous Cell Carcinoma: A 3-Case Report and Literature Review. ( 30107162 )
2018
41
The largest reported papillary thyroid carcinoma arising in struma ovarii and metastasis to opposite ovary: case report and review of literature. ( 30061934 )
2018
42
An unusual presentation of a papillary thyroid carcinoma in the struma ovarii in a 10 year-old girl: A case report. ( 30196119 )
2018
43
Cytodiagnosis of Primary Thyroid Lymphoma Coincident with Unnoticed Papillary Thyroid Carcinoma: A Case Report and Review of the Literature. ( 30089952 )
2018
44
Sonographic Characteristics of Papillary Thyroid Carcinoma with Coexistent Hashimoto's Thyroiditis: Conventional Ultrasound, Acoustic Radiation Force Impulse Imaging and Contrast-Enhanced Ultrasound. ( 30528690 )
2018
45
Relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma in children and adolescents. ( 30536322 )
2018
46
Warthin-like papillary thyroid carcinoma with immunoglobulin G4-positive plasma cells possibly related to Hashimoto's thyroiditis. ( 29093307 )
2018
47
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. ( 29316976 )
2018
48
Identification of differentiated functional modules in papillary thyroid carcinoma by analyzing differential networks. ( 30539831 )
2018
49
An unusual presentation of papillary thyroid carcinoma in a pediatric patient: A case report. ( 30540894 )
2018
50
FKBP51 promotes migration and invasion of papillary thyroid carcinoma through NF-κB-dependent epithelial-to-mesenchymal transition. ( 30546435 )
2018

Variations for Thyroid Cancer, Nonmedullary, 1

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

75
# Symbol AA change Variation ID SNP ID
1 NKX2-1 p.Ala339Val VAR_075769 rs537209983

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
2 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
3 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
4 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh37 Chromosome 14, 36986583: 36986583
5 NKX2-1 NM_001079668.2(NKX2-1): c.1106C> T (p.Ala369Val) single nucleotide variant Likely benign rs537209983 GRCh38 Chromosome 14, 36517378: 36517378
6 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh37 Chromosome 8, 17823587: 17823587
7 PCM1 NM_006197.3(PCM1): c.2935C> T (p.Gln979Ter) single nucleotide variant Uncertain significance rs1085307084 GRCh38 Chromosome 8, 17966078: 17966078

Cosmic variations for Thyroid Cancer, Nonmedullary, 1:

9 (show top 50) (show all 293)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 55
2 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 55
3 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 55
4 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 55
5 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 55
6 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 55
7 COSM10867 TP53 thyroid,NS,carcinoma,papillary carcinoma c.797G>A p.G266E 17:7673823-7673823 55
8 COSM10704 TP53 thyroid,NS,carcinoma,papillary carcinoma c.844C>T p.R282W 17:7673776-7673776 55
9 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 55
10 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 55
11 COSM43980 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 55
12 COSM10863 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 55
13 COSM44988 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 55
14 COSM10771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 55
15 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 55
16 COSM10834 TP53 thyroid,NS,carcinoma,papillary carcinoma c.711G>A p.M237I 17:7674252-7674252 55
17 COSM6959677 SYK thyroid,NS,carcinoma,papillary carcinoma c.65G>A p.R22Q 9:90843963-90843963 55
18 COSM6974249 SPEN thyroid,NS,carcinoma,papillary carcinoma c.10348C>T p.Q3450* 1:15937484-15937484 55
19 COSM14195 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.1482C>T p.D494D 18:51078290-51078290 55
20 COSM14186 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.788A>G p.N263S 18:51058340-51058340 55
21 COSM14163 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.931C>T p.Q311* 18:51059892-51059892 55
22 COSM14185 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.676G>A p.A226T 18:51058133-51058133 55
23 COSM14189 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.971G>A p.C324Y 18:51065438-51065438 55
24 COSM14196 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.1648C>T p.P550S 18:51078456-51078456 55
25 COSM14193 SMAD4 thyroid,NS,carcinoma,papillary carcinoma c.1487G>A p.R496H 18:51078295-51078295 55
26 COSM3407453 SF3B1 thyroid,NS,carcinoma,papillary carcinoma c.1781G>A p.R594Q 2:197402974-197402974 55
27 COSM6954357 SETD2 thyroid,NS,carcinoma,papillary carcinoma c.3247C>G p.H1083D 3:47106080-47106080 55
28 COSM6945083 RICTOR thyroid,NS,carcinoma,papillary carcinoma c.2539C>T p.L847F 5:38955665-38955665 55
29 COSM3390655 RBM10 thyroid,NS,carcinoma,papillary carcinoma c.2548C>T p.Q850* 23:47186268-47186268 55
30 COSM6981514 RBM10 thyroid,NS,carcinoma,papillary carcinoma c.853C>T p.Q285* 23:47179447-47179447 55
31 COSM6944613 RBM10 thyroid,NS,carcinoma,papillary carcinoma c.1573C>T p.Q525* 23:47181644-47181644 55
32 COSM6917469 RAD51B thyroid,NS,carcinoma,papillary carcinoma c.940G>C p.D314H 14:68411510-68411510 55
33 COSM6944180 RAD50 thyroid,NS,carcinoma,papillary carcinoma c.3057A>T p.Q1019H 5:132637199-132637199 55
34 COSM6923704 PTPRT thyroid,NS,carcinoma,papillary carcinoma c.3655G>T p.G1219W 20:42102249-42102249 55
35 COSM6961568 PTPRD thyroid,NS,carcinoma,papillary carcinoma c.1616C>G p.P539R 9:8507362-8507362 55
36 COSM13015 PTPN11 thyroid,NS,carcinoma,papillary carcinoma c.215C>T p.A72V 12:112450395-112450395 55
37 COSM5092 PTEN thyroid,NS,carcinoma,papillary carcinoma c.385G>A p.G129R 10:87933144-87933144 55
38 COSM5064 PTEN thyroid,NS,carcinoma,papillary carcinoma c.44G>A p.R15K 10:87864513-87864513 55
39 COSM4016454 PTEN thyroid,NS,carcinoma,papillary carcinoma c.295G>A p.E99K 10:87933054-87933054 55
40 COSM5034 PTEN thyroid,NS,carcinoma,papillary carcinoma c.425G>A p.R142Q 10:87933184-87933184 55
41 COSM3394847 PMS2 thyroid,NS,carcinoma,papillary carcinoma c.206C>T p.S69L 7:6004016-6004016 55
42 COSM763 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1633G>A p.E545K 3:179218303-179218303 55
43 COSM29106 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1658G>A p.S553N 3:179218328-179218328 55
44 COSM29110 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3115T>C p.F1039L 3:179234272-179234272 55
45 COSM33701 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1589A>G p.Q530R 3:179218259-179218259 55
46 COSM776 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3140A>T p.H1047L 3:179234297-179234297 55
47 COSM778 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.2102A>C p.H701P 3:179221072-179221072 55
48 COSM775 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3140A>G p.H1047R 3:179234297-179234297 55
49 COSM12597 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.3145G>C p.G1049R 3:179234302-179234302 55
50 COSM29314 PIK3CA thyroid,NS,carcinoma,papillary carcinoma c.1598C>T p.A533V 3:179218268-179218268 55

Copy number variations for Thyroid Cancer, Nonmedullary, 1 from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13343 1 1 124300000 Chromosomal rearrang ement Papillary thyroid carcinoma
2 13804 1 1 60900000 Chromosomal rearrang ement Papillary thyroid carcinoma
3 19995 1 152394403 152431233 Translate TPM3 Papillary thyroid carcinoma
4 42899 10 42100000 53300000 Chromosomal rearrang ement Papillary thyroid carcinoma
5 44673 10 61218526 61336824 Translate D10S170 Papillary thyroid carcinoma
6 91970 15 37900000 47600000 Copy number FGF7 Papillary thyroid carcinoma
7 95418 15 76100000 86900000 Copy number AKAP13 Papillary thyroid carcinoma
8 96732 15 92330402 92376057 Translate GOLGA5 Papillary thyroid carcinoma
9 106730 17 1 11200000 Copy number TRE2 Papillary thyroid carcinoma
10 140387 2 197100000 209100000 Copy number TRAK2 Papillary thyroid carcinoma
11 148729 2 83700000 91000000 Amplification TB10 Papillary thyroid carcinoma
12 166063 3 1 14700000 Chromosomal rearrang ement Papillary thyroid carcinoma
13 166395 3 101910849 101950501 Translate TFG Papillary thyroid carcinoma
14 194280 5 139000000 143100000 Copy number EIF4EBP3 Papillary thyroid carcinoma
15 219438 7 126900000 158821424 Chromosomal rearrangement Papillary thyroid carcinoma
16 232143 8 112100000 146364022 Amplification Papillary thyroid cancer

Expression for Thyroid Cancer, Nonmedullary, 1

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 1.

Pathways for Thyroid Cancer, Nonmedullary, 1

Pathways related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.51 MIR221 MIR222
2 9.7 HOTAIR LINC-ROR

GO Terms for Thyroid Cancer, Nonmedullary, 1

Biological processes related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of epithelial cell migration GO:0010634 9.51 MIR221 MIR222
2 positive regulation of erythrocyte differentiation GO:0045648 9.49 MIR221 MIR222
3 thyroid gland development GO:0030878 9.48 BRAF NKX2-1
4 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.46 MIR221 MIR222
5 negative regulation by host of viral genome replication GO:0044828 9.43 MIR221 MIR222
6 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.4 MIR221 MIR222
7 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR221 MIR222
8 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.32 MIR221 MIR222
9 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR221 MIR222
10 positive regulation of Schwann cell migration GO:1900149 9.16 MIR221 MIR222
11 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222
12 positive regulation of axon regeneration GO:0048680 8.8 BRAF MIR221 MIR222

Sources for Thyroid Cancer, Nonmedullary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....